Glassia
[Alpha$_1$-Proteinase Inhibitor (Human)]

For your patients with severe Alpha$_1$-antitrypsin deficiency with clinically evident emphysema

GIVE YOUR PATIENTS THE FREEDOM TO INFUSE ON THEIR TERMS

LINDA
Real GLASSIA patient since 2011
Avid traveler
Self-infuses at home

GLASSIA® offers the most weekly administration setting options.

- AT HOME SELF-ADMIN*
- AT HOME WITH NURSE
- AT INFUSION CENTER
- AT CLINIC

The only FDA-approved, self-administration at home option for patients to help raise their Alpha$_1$ levels.

*If self-administration is deemed appropriate, ensure that the patient/caregiver receives detailed instructions and adequate training on how to administer in the home or other appropriate setting and has demonstrated the ability to independently administer GLASSIA.

INDICATION AND LIMITATIONS OF USE:

GLASSIA is an Alpha$_1$-Proteinase Inhibitor (Human) (Alpha$_1$-PI) indicated for chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe hereditary deficiency of Alpha$_1$-PI (alpha$_1$-antitrypsin deficiency).

The effect of augmentation therapy with GLASSIA or any Alpha$_1$-PI product on pulmonary exacerbations and on the progression of emphysema in Alpha$_1$-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trials. Clinical data demonstrating the long-term effects of chronic augmentation and maintenance therapy of individuals with GLASSIA are not available. GLASSIA is not indicated as therapy for lung disease in patients in whom severe Alpha$_1$-PI deficiency has not been established.

IMPORTANT SAFETY INFORMATION

Contraindications

- **Immunoglobulin A (IgA) deficient patients with antibodies against IgA**
- **History of anaphylaxis or other severe systemic reaction to Alpha$_1$-PI products.**

Please see additional Important Safety Information on next page and click for GLASSIA Full Prescribing Information.

Glassia
[Alpha$_1$-Proteinase Inhibitor (Human)]

GLASSIA offers your patients with severe Alpha$_1$-antitrypsin deficiency:

FLEXIBILITY

The first and only Alpha$_1$ augmentation therapy approved for self-administration, with a wide range of administration setting options that gives you and your patients the freedom to choose what works best for them[1]*

TRUST

Trusted by HCPs for over a decade to increase Alpha$_1$ levels[1]

RESOURCES

Get access to resources to help educate your patients and the forms to get them started

For more information, please click to download the GLASSIA® Start Form and Full Prescribing Information.

Click to visit glassialiquid.com/hcp for more information and resources for your office.

*If self-administration is deemed appropriate, ensure that the patient/caregiver receives detailed instructions and adequate training on how to administer in the home or other appropriate setting and has demonstrated the ability to independently administer GLASSIA.

Takeda Patient Support

When you prescribe GLASSIA for your patient, Takeda Patient Support is here for them.

IMPORTANT SAFETY INFORMATION, CONTINUED

Warnings and Precautions

Hypersensitivity: GLASSIA may contain trace amounts of IgA. Monitor vital signs continuously and observe the patient throughout the infusion. If hypersensitivity symptoms occur, discontinue the infusion and administer appropriate emergency treatment. Have epinephrine and/or other appropriate supportive therapy available for any acute anaphylactic or anaphylactoid reaction.

Transmissible Infectious Agents: Because GLASSIA is made from human plasma it may carry a risk of transmitting infectious agents such as viruses, the variant Creutzfeldt-Jakob disease (vCJD) and theoretically, the Creutzfeldt-Jakob disease (CJD) agent and other pathogens. No seroconversions for hepatitis B or C or human immunodeficiency virus or any other known infectious agent were reported with the use of GLASSIA during the clinical trials.

Adverse Reactions

The serious adverse reaction observed during clinical trials with GLASSIA was exacerbation of chronic obstructive pulmonary disease (COPD).

The most common adverse reactions during clinical trials were headache and upper respiratory infection.

Please click for GLASSIA Full Prescribing Information.

REFERENCE: 1. GLASSIA. Prescribing information. Takeda Pharmaceuticals U.S.A., Inc.; 2023.

US-GLA-0438v1.0 03/24

Takeda